Shefali Agarwal - Feb 2, 2022 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role
Executive Vice President, Chief Medical and Development Officer
Signature
/s/ John Weidenbruch, attorney-in-fact
Stock symbol
EPZM
Transactions as of
Feb 2, 2022
Transactions value $
-$3,615
Form type
4
Date filed
2/4/2022, 03:15 PM
Previous filing
Jan 28, 2022
Next filing
Feb 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Sale -$3.62K -2.64K -1.65% $1.37 157K Feb 2, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Company's 2013 Stock Incentive Plan on February 1, 2021. The automatic sale of the reporting person's shares of Common Stock is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.

Remarks:

Executive Vice President, Chief Medical and Development Officer